1SXP — SCHOTT Pharma AG & Co KgaA Cashflow Statement
0.000.00%
- €3.57bn
- €3.64bn
- €957.09m
- 64
- 11
- 15
- 17
Annual cashflow statement for SCHOTT Pharma AG & Co KgaA, fiscal year end - September 30th, EUR millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | — | — | — | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 77.6 | 101 | 126 | 152 | 150 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 3.65 | 9.86 | 25 | -2.1 | -2.47 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -9.16 | -17 | -27.3 | -15.7 | 16.7 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 104 | 132 | 182 | 182 | 225 |
Capital Expenditures | -85.3 | -98.6 | -153 | -176 | -145 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 4.09 | 2.73 | 10.6 | 4.11 | -0.633 |
Sale of Fixed Assets | |||||
Purchase of Investments | |||||
Sale of Intangible Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -81.2 | -95.9 | -142 | -171 | -146 |
Financing Cash Flow Items | -14.3 | -26 | -40.9 | 11 | -52 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -14.4 | -27.5 | -42.4 | -11.4 | -78.2 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.95 | 9.25 | 0.935 | -4.44 | -1.18 |